Deutsche Bank AG Makes New $7.86 Million Investment in Inspire Medical Systems, Inc. $INSP

Key Points

• Deutsche Bank acquired 176,200 shares of Inspire Medical Systems in the second quarter, valued at approximately $7.86 million and representing about 0.61% of the company. Institutional investors and hedge funds collectively own 94.91% of the stock.
• Inspire reported quarterly earnings of $0.14 per share, beating the consensus estimate of a $0.24 loss, while revenue reached $200.58 million—above expectations but down 7.6% year over year.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and $66.19 average price target. Shares recently opened at $62.45, above their 50-day and 200-day moving averages.

Deutsche Bank AG purchased a new stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund purchased 176,200 shares of the company's stock, valued at approximately $7,860,000. Deutsche Bank AG owned about 0.61% of Inspire Medical Systems as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Alberta Investment Management Corp purchased a new stake in Inspire Medical Systems in the second quarter valued at approximately $5,483,000. Assenagon Asset Management S.A. raised its position in Inspire Medical Systems by 66.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 864,395 shares of the company's stock worth $38,561,000 after buying an additional 344,221 shares during the last quarter. Bank of Nova Scotia lifted its stake in Inspire Medical Systems by 49.8% during the 1st quarter. Bank of Nova Scotia now owns 60,000 shares of the company's stock valued at $3,095,000 after acquiring an additional 19,958 shares during the period. GSA Capital Partners LLP acquired a new stake in Inspire Medical Systems during the 2nd quarter valued at approximately $820,000. Finally, Empowered Funds LLC acquired a new stake in Inspire Medical Systems during the 1st quarter valued at approximately $1,799,000. 94.91% of the stock is owned by institutional investors and hedge funds.

Inspire Medical Systems Price Performance

Shares of NYSE:INSP opened at $62.45 on Monday. The business's 50 day moving average price is $51.14 and its 200-day moving average price is $52.62. Inspire Medical Systems, Inc. has a 1 year low of $38.91 and a 1 year high of $147.03. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of 13.52, a price-to-earnings-growth ratio of 4.74 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The firm had revenue of $200.58 million during the quarter, compared to the consensus estimate of $194.72 million. During the same quarter in the prior year, the firm earned $0.45 EPS. The company's revenue for the quarter was down 7.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, sell-side analysts expect that Inspire Medical Systems, Inc. will post 1.24 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on INSP shares. Weiss Ratings upgraded shares of Inspire Medical Systems from a "sell (d)" rating to a "sell (d+)" rating in a research note on Wednesday. Evercore set a $54.00 price target on shares of Inspire Medical Systems in a report on Tuesday, August 4th. Truist Financial reiterated a "hold" rating and set a $62.00 price objective (up from $54.00) on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Zacks Research upgraded Inspire Medical Systems from a "hold" rating to a "strong-buy" rating in a research note on Monday, August 17th. Finally, KeyCorp restated a "sector weight" rating on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $66.19.

Insider Activity at Inspire Medical Systems

In other news, insider Jason P. Kelly sold 963 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the sale, the insider directly owned 18,985 shares in the company, valued at $1,130,556.75. This represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.20% of the stock is owned by company insiders.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

Want to see what other hedge funds are holding INSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inspire Medical Systems, Inc. (NYSE:INSP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source